MEETING VENUE HOTEL MICHELANGELO MILAN Piazza Luigi di Savoia, 6 - 20124 Milan, Italy Tel: +39 0267551 MEETING SECRETARIAT AND CME PROVIDER MI&T Srl Viale Carducci, 50 - 40125 Bologna - Italy Tel. +39 051 220427 Fax +39 051 0822077 [email protected]www.mitcongressi.it REGISTRATION FEE ELITA/ESOT Member € 100,00 - NonMember € 250,00 to register please access www.mitcongressi.it and click on ELITA/ESOT Monothematic Conference LIVER TRANSPLANTATION IN HCV OR HBV POSITIVE RECIPIENTS: WHERE WE ARE AND WHERE WE ARE GOING UNRESTRICTED GRANT BY ELITA/ESOT Monothematic Conference LIVER TRANSPLANTATION IN HCV OR HBV POSITIVE RECIPIENTS: WHERE WE ARE AND WHERE WE ARE GOING MILANO April 1, 2016 HOTEL MICHELANGELO Christophe Duvoux CHAIR Roberto Troisi VICE-CHAIR Wojtek Polak SECRETARY Gabriela Berlakovich TREASURER Renè Adam CUSTODIAN Luca Saverio Belli William Bennet Giacomo Germani Silvio Nadalin Martin Oliverius Krzysztof Zieniewicz Luca Saverio Belli Christophe Duvoux SILVER SPONSOR
2
Embed
LIVER REGISTRATION FEE TRANSPLANTATION IN HCV OR HBV ...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
MEETING VENUEHOTEL MICHELANGELO MILAN
Piazza Luigi di Savoia, 6 - 20124 Milan, ItalyTel: +39 0267551
REGISTRATION FEEELITA/ESOT Member € 100,00 - NonMember € 250,00
to register please access www.mitcongressi.it and click on ELITA/ESOT Monothematic Conference
LIVEr TrANSPLANTATION IN HCV Or HBV POSITIVE rECIPIENTS: wHErE wE ArE ANd wHErE wE ArE GOING
UNRESTRICTED GRANT BY
ELITA/ESOT Monothematic Conference
LIVER TRANSPLANTATIONIN HCV OR HBV POSITIVE RECIPIENTS: wHERE wE ARE AND wHERE wE ARE GOING
MILANOApril 1, 2016HOTEL MICHELANGELO
Christophe DuvouxCHAIr
roberto TroisiVICE-CHAIr
wojtek PolakSECrETArY
Gabriela BerlakovichTrEASUrEr
renè AdamCUSTOdIAN
Luca Saverio Belliwilliam Bennet
Giacomo GermaniSilvio Nadalin
Martin Oliverius Krzysztof Zieniewicz
Luca Saverio BelliChristophe Duvoux
SILVEr SPONSOr
8:00> 8:10 welcome and Introduction: L.S. Belli and C. Duvoux
8:10>10:30 SESSION 1 Antiviral therapy for HCV in the setting of Liver transplantation. what’s new since the ELITA Milan Conference 2015 Chairs: P. Burra and M. Berenguer
8:10>8:40 Summing up of 2015 ELITA guidelines L.S. Belli and C. Duvoux
8:40>8:55 The new weapons and their combinations in early 2016: what will change the landscape in compensated and de-compensated cirrhotics? T. Berg
8:55>9:10 Up-date on safety, post marketing toxicity and recent alerts of DAAs C. Hezode
9:10>9:25 DAAs and virological resistance in the setting of Liver transplantation: pre LT and pre ReLT resistance M. Puoti
9:25>9:35 Q&A
9:35>9:50 DAA in de-compensated cirrhotics: focus on possible de-listing L.S. Belli
9:50>10:05 Use of HCV positive Liver grafts in the DAA Era: can we reconsider it? M. Berenguer
10:05>10:20 Value-based Hepatology aspects: the clinician point of view. Focus on pre and post LT DAAs treatments and expected cost reductions M. Strazzabosco
10:20>10:30 Q&A
10:30>10:50 Coffee break 10:50>11:45 SESSION 2 ELITA guidelines for DAA use in the Liver transplant setting: time for an update
Round table M. Berenguer, I. Colle, T. Berg, S. Fagiuoli, G. Pageaux, M. Londoño, C. Hezode
11:45>12:35 SESSION 3 HBV infection and Liver transplantation: epidemiology and pre LT management Introduction: C. Duvoux Chairs: P. Muiesan and L. De Carlis
11:45>12:00 HBV/HDV and LT. Data from ELTR P. Burra
12:00>12:15 Impact of NUC therapy on Liver function in decompensated cirrhosis and virological criteria to be eligible for LT F. Durand
12:15>12:35 Prophylactic strategies in Europe in 2016. French and Italian surveys: the landscape C. Duvoux and R. Volpes
12:35>13:30 Lunch Break
13:30>15:30 SESSION 4 Management of HBV: transplant and post transplant issues Chairs: W. Polak and M. Buti
13:30>13:50 Is there a Virological rationale to combine NUC and HBIg in 2015? C. Feray
13:50>14:10 Combined HBIG/NUC prophylaxis: time for selective HBIG withdrawal long term? R. Esteban
14:10>14:30 Is 3rd generation “NUCs alone prophylaxis” after LT a safe option? J. Fung
Just a focus on:
14:30>14:45 Anti HBc+ve Liver grafts: which prophylaxis in which recipients? A. Coilly
14:45>15:00 HBsAg+ve grafts: which prophylaxis in which recipients? P. Andreone
15:00>15:15 HDV and Liver Transplantation: do HDV+ve recipients require a specific prophylaxis? M. Rizzetto
15:15>15:30 Vaccination for HBV and Liver transplantation: what’s new? F. Nevens
15:30>15:45 Coffee break
15:45>16:45 SESSION 5 Controversial aspects of HBV in the Liver transplant setting
Round table M. Rizzetto, M. Berenguer, M. Buti, R. Romagnoli, J. Fung, F. Nevens, F. Durand
16:45>17:00 An attempt to define the best decision making algorithm for HBV prophylaxis after Liver transplantation M. Buti